期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
我国制药业研究开发与国际水平的差距及对策
1
作者 王毅 陈劲 《中国地质大学学报(社会科学版)》 2001年第3期6-10,共5页
文本首先比较了我国与全球领先制药公司研究开发的差距。作者认为 ,我国制药业在资源投入上难以与他们抗衡。但从日本制药公司及西方成功制药公司的经验来看 ,我国制药业可以通过加强创新管理来弥补其不足 。
关键词 制药业研究开发 全球高标准 创新管理
下载PDF
Towards efficiency in rare disease research: what is distinctive and important? 被引量:3
2
作者 Jinmeng Jia Tieliu Shi 《Science China(Life Sciences)》 SCIE CAS CSCD 2017年第7期686-691,共6页
Characterized by their low prevalence, rare diseases are often chronically debilitating or life threatening. Despite their low prevalence, the aggregate number of individuals suffering from a rare disease is estimated... Characterized by their low prevalence, rare diseases are often chronically debilitating or life threatening. Despite their low prevalence, the aggregate number of individuals suffering from a rare disease is estimated to be nearly 400 million worldwide.Over the past decades, efforts from researchers, clinicians, and pharmaceutical industries have been focused on both the diagnosis and therapy of rare diseases. However, because of the lack of data and medical records for individual rare diseases and the high cost of orphan drug development, only limited progress has been achieved. In recent years, the rapid development of next-generation sequencing(NGS)-based technologies, as well as the popularity of precision medicine has facilitated a better understanding of rare diseases and their molecular etiology. As a result, molecular subclassification can be identified within each disease more clearly, significantly improving diagnostic accuracy. However, providing appropriate care for patients with rare diseases is still an enormous challenge. In this review, we provide a brief introduction to the challenges of rare disease research and make suggestions on where and how our efforts should be focused. 展开更多
关键词 rare disease rare disease diagnosis and treatment data standard data sharing orphan drugs
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部